|

Autologous CCR4 CAR T cells Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Subacute Panniculitis-like T-cell Lymphoma1
  • Monomorphic Epithelialtropic Intestinal Lymphoma1
  • Relapsed and/or Refractory Mature T Cell Malignancy1
  • Hepatosplenic T-cell Lymphoma1
  • Enteropathy-associated T-cell Lymphoma1

Bethesda, Maryland1 trial

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

National Institutes of Health Clinical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.